The latest price target for Salarius Pharmaceuticals (NASDAQ:SLRX) was reported by HC Wainwright & Co. on March 11, 2022. The analyst firm set a price target for $4.00 expecting SLRX to rise to within 12 months (a possible 185.71% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Salarius Pharmaceuticals (NASDAQ:SLRX) was provided by HC Wainwright & Co., and Salarius Pharmaceuticals maintained their buy rating.

There is no last upgrade for Salarius Pharmaceuticals

There is no last downgrade for Salarius Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Salarius Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Salarius Pharmaceuticals was filed on March 11, 2022 so you should expect the next rating to be made available sometime around March 11, 2023.

While ratings are subjective and will change, the latest Salarius Pharmaceuticals (SLRX) rating was a maintained with a price target of $5.00 to $4.00. The current price Salarius Pharmaceuticals (SLRX) is trading at is $1.40, which is out of the analyst’s predicted range.